Genome-wide association studies (GWAS) have identified robust and reproducible loci that contribute to NAFLD pathogenesis and variability of prognosis, including the non-synonymous single nucleotide polymorphisms (SNPs) in PNPLA3 (phospholipase domain-containing 3), TM6SF2 (transmembrane 6 superfamily member 2), MBOAT7 (membrane-bound O-acyltransferase domain-containing protein 7), GCKR (glucokinase regulator), and HSD17B13 (17-beta hydroxysteroid dehydrogenase 13) [9]. Here, HSD17B13 is linked to metabolic dysfunction-associated steatotic liver disease.